MY205182A - Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine - Google Patents

Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine

Info

Publication number
MY205182A
MY205182A MYPI2020001094A MYPI2020001094A MY205182A MY 205182 A MY205182 A MY 205182A MY PI2020001094 A MYPI2020001094 A MY PI2020001094A MY PI2020001094 A MYPI2020001094 A MY PI2020001094A MY 205182 A MY205182 A MY 205182A
Authority
MY
Malaysia
Prior art keywords
migraine
lasmiditan
treatment
combination therapy
cgrp antagonist
Prior art date
Application number
MYPI2020001094A
Other languages
English (en)
Inventor
Henry Krege John
Willis Johnson Kirk
Aurora Sheena
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MY205182A publication Critical patent/MY205182A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
MYPI2020001094A 2017-09-06 2018-08-30 Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine MY205182A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762554726P 2017-09-06 2017-09-06
PCT/US2018/048730 WO2019050759A1 (en) 2017-09-06 2018-08-30 POLYTHERAPY OF LASMIDITAN AND CGRP ANTAGONIST FOR USE IN THE TREATMENT OF MIGRAINE

Publications (1)

Publication Number Publication Date
MY205182A true MY205182A (en) 2024-10-04

Family

ID=63529021

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020001094A MY205182A (en) 2017-09-06 2018-08-30 Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine

Country Status (17)

Country Link
US (1) US20200268735A1 (enExample)
EP (2) EP3678665A1 (enExample)
JP (5) JP6922092B2 (enExample)
KR (2) KR20230025945A (enExample)
CN (3) CN111032044A (enExample)
AU (1) AU2018329568B2 (enExample)
BR (1) BR112020002077A2 (enExample)
CA (1) CA3073996C (enExample)
EA (1) EA202090457A1 (enExample)
IL (2) IL314347A (enExample)
MA (2) MA71474A (enExample)
MX (2) MX2020002554A (enExample)
MY (1) MY205182A (enExample)
SG (1) SG11202001387WA (enExample)
TW (1) TWI754772B (enExample)
WO (1) WO2019050759A1 (enExample)
ZA (1) ZA202000443B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2413933T4 (da) 2009-04-02 2021-08-23 Colucid Pharmaceuticals Inc 2,4,6-trifluor-N-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamid til behandling af migræne via oral eller intravenøs indgivelse
TWI692485B (zh) * 2011-05-20 2020-05-01 美商艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途
CN112022818A (zh) 2014-02-05 2020-12-04 默沙东公司 Cgrp-活性化合物的片剂制剂
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
US11717515B2 (en) 2020-12-22 2023-08-08 Allergan Pharmaceuticals International Limited Treatment of migraine
CA3043772C (en) 2016-12-06 2022-06-07 Colucid Pharmaceuticals, Inc. Hydrates of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and uses thereof as a 5-ht1f agonist
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
US20190374518A1 (en) * 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
PH12021551689A1 (en) * 2019-01-20 2022-05-11 Pfizer Ireland Pharmaceuticals Cgrp antagonists for treating migraine breakthrough
TWI776175B (zh) 2019-07-09 2022-09-01 美商美國禮來大藥廠 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備
EP4188375A4 (en) 2020-07-29 2024-07-24 Allergan Pharmaceuticals International Limited MIGRAINE TREATMENT
MX2024003952A (es) 2021-09-27 2024-05-27 Allergan Pharmaceuticals Int Ltd Combinación que comprende atogepant para tratar la migraña.
CN116270505A (zh) * 2021-12-20 2023-06-23 南京科默生物医药有限公司 含半琥珀酸拉司米地坦的口服固体制剂及其3d打印制备技术
JP7499538B1 (ja) 2023-03-29 2024-06-14 ロゴスサイエンス株式会社 慢性疼痛の治療、改善およびセルフケアシステム

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002353D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New use
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
WO2005046659A2 (en) * 2003-11-12 2005-05-26 Nps Pharmaceuticals, Inc. Migraine treatments including isovaleramide compounds and serotonin agonists
WO2011123654A1 (en) * 2010-04-02 2011-10-06 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists
AR081434A1 (es) * 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
AU2017331593B2 (en) * 2016-09-23 2022-04-28 Teva Pharmaceuticals International Gmbh Treating refractory migraine
RU2770066C2 (ru) * 2017-03-02 2022-04-14 Бет Изрейэл Диконисс Медикал Сентер, Инк. Отбор пациентов с головной болью, восприимчивых к антителам, направленным против кальцитонин ген-родственного пептида
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法

Also Published As

Publication number Publication date
MX2023008760A (es) 2023-08-02
JP6922092B2 (ja) 2021-08-18
KR20200036919A (ko) 2020-04-07
ZA202000443B (en) 2022-07-27
JP2023029872A (ja) 2023-03-07
CA3073996A1 (en) 2019-03-14
AU2018329568A1 (en) 2020-02-06
NZ761634A (en) 2024-05-31
EA202090457A1 (ru) 2020-06-10
EP4397317A3 (en) 2024-10-16
IL314347A (en) 2024-09-01
CA3073996C (en) 2022-05-31
CN116059204A (zh) 2023-05-05
JP2020530861A (ja) 2020-10-29
TW201919624A (zh) 2019-06-01
JP2021176884A (ja) 2021-11-11
BR112020002077A2 (pt) 2020-07-28
SG11202001387WA (en) 2020-03-30
JP7711255B2 (ja) 2025-07-22
MX2020002554A (es) 2020-07-13
US20200268735A1 (en) 2020-08-27
TWI754772B (zh) 2022-02-11
MA50073A (fr) 2020-07-15
KR20230025945A (ko) 2023-02-23
CN116509861A (zh) 2023-08-01
EP4397317A2 (en) 2024-07-10
WO2019050759A1 (en) 2019-03-14
JP2024109585A (ja) 2024-08-14
JP7480261B2 (ja) 2024-05-09
EP3678665A1 (en) 2020-07-15
AU2018329568B2 (en) 2021-09-23
MA71474A (fr) 2025-04-30
IL273031A (en) 2020-04-30
JP7183355B2 (ja) 2022-12-05
CN111032044A (zh) 2020-04-17
JP2025165940A (ja) 2025-11-05

Similar Documents

Publication Publication Date Title
MX2023008760A (es) Terapia combinada de lasmiditan y un antagonista de cgrp para el uso en el tratamiento de la migra?a.
PH12017502103A1 (en) Methods and kits for treating depression
PH12021550448A1 (en) Chronic nightly dosing of lasmiditan for migraine prevention.
PH12017501934A1 (en) Methods for treating or preventing migraine headache
MX2023009483A (es) Anticuerpos monoclonales para usarse para el tratamiento de sinucleinopatia.
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
PH12021551689A1 (en) Cgrp antagonists for treating migraine breakthrough
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
ZA202005388B (en) Methods of treating ulcerative colitis
MX2018012493A (es) Métodos para controlar y tratar el cáncer.
MX371153B (es) Nuevos compuestos como inhibidores de la cinasa inductora de nf-kb (nik).
MX371150B (es) NUEVOS DERIVADOS DE PIRAZOL EN CALIDAD DE INHIBIDORES DE LA CINASA INDUCTORA DE NF-kB (NIK).
MX371152B (es) Nuevos derivados de pirazolopirimidina como inhibidores de la cinasa inductora de nf-kb (nk).
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
PH12021550122A1 (en) Solubilized apyrases, methods and use
MX2017000306A (es) Metodos para tratar hipotension.
PH12019500075A1 (en) Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders
MX2020001164A (es) Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico.
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX2017007318A (es) Metodos de prevencion, reduccion o tratamiento de degeneracion macular.
MX2017002093A (es) Terapia con anticuerpos para vih como sustituto de tratamiento.
MX2020005557A (es) Agonistas de fxr para el tratamiento de enfermedades hepaticas.
GEP20197007B (en) Therapeutic agent for frontal lobe dysfunction
GB2546703A (en) Compounds